The partnership will leverage RaQualia’s core expertise in drug discovery and development, and Interprotein’s platform technology, INTerprotein’s Engine for New Drug Design (INTENDD).
Under the agreement, RaQualia will provide Interprotein with upfront payment, contingency payment and further research milestones.
RaQualia said it will be eligible to receive the exclusive rights of all results from the collaborative research.
PPI, a biological responses produced by binding of two or more protein molecules, plays an important role in the pathophysiology of many diseases.